Cardium Therapeutics announced earlier this year that it had arranged a distribution venture with Academy Medical for marketing, sale, and distribution of Excellagen, an FDA-cleared advanced gel with the ability to speed up the healing of various wounds. Perhaps the … Continue reading →

Cardium Therapeutics today presented its financial results for the first quarter ended March 31, 2013, and reported on highlights and other recent developments. The company narrowed its first-quarter loss to $2.2 million from a net loss of $2.6 million for … Continue reading →

As hard as it may seem to believe, the American Diabetes Association says that over 8% of the U.S. population, roughly 1 out of 12 Americans, now has diabetes. That’s nearly 26 million people, though perhaps 1/4 of those afflicted … Continue reading →

Cardium Therapeutics, an asset-based health sciences and regenerative medicine company, today highlighted the publication, “Mechanistic, Technical, and Clinical Perspectives in Therapeutic Stimulation of Coronary Collateral Development by Angiogenic Growth Factors,” authored by Gabor M Rubanyi, M.D., Ph.D., Cardium’s chief scientific … Continue reading →

Cardium Therapeutics, an asset-based health sciences and regenerative medicine company, is scheduled to present a poster demonstrating the clinical benefits of its lead commercial product, Excellagen®, at The Symposium on Advanced Wound Care and Wound Healing Society (SAWC/WHS) meeting to … Continue reading →

Cardium Therapeutics is a San Diego based health sciences and regenerative medicine company that has carefully diversified itself with a strategy designed to provide short-term, mid-term, and long-term growth and revenue. In so doing, they have successfully positioned themselves in … Continue reading →

When Cardium Therapeutics recently released their 2012 financial results, reflecting the company’s extensive investment required for the important introduction of Excellagen and nutraceutical initiatives, and the initiation of their Generx ASPIRE clinical study, the standout feature of the report was … Continue reading →

Cardium Therapeutics, a medical technology company focused on cardiovascular and tissue repair, has developed and is implementing a comprehensive commercialization strategy for Excellagen, the company’s novel syringe-based gel to boost the healing process for all types of wounds, including diabetic … Continue reading →

Today before the opening bell, Cardium made a series of announcements as well as provided a comprehensive update on its ongoing initiatives. An abridged overview is presented below due to the length of the press releases issued. For detailed information, … Continue reading →

The number and degree of medical advances over the past 50 years is astonishing, offering hope for the afflicted never before possible or even imaginable. But it’s hope that comes with a very steep price. Regardless of who pays the … Continue reading →